Sanofi’s Rezurock recommended for EU approval by the CHMP to treat chronic graft-vs-host disease Recommendation supported by safety and efficacy results from several clinical studies and real-world evidenceIf approved, Rezurock would offer a new treatment option in the EU for adult patients and in children aged 12 years and older in late line chronic GVHD Paris, January 30, 2026. The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending ...

Sanofi’s Rezurock recommended for EU approval by the CHMP to treat chronic graft-vs-host disease Recommendation supported by safety and efficacy results from several clinical studies and real-world evidenceIf approved, Rezurock would offer a new treatment option in the EU for adult patients and in children aged 12 years and older in late line chronic GVHD Paris, January 30, 2026. The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending ...

全球最新、最好的创新药物，什么时候能来中国？跨国药企赛诺菲正在用实际行动表明，中国可以是全球新药"第一站"。 2025年12月到2026年1月，短短数周内，赛诺菲连续有两款心血管药物在中国获批。它们分别是全球首发的新药阿夫凯泰片（商品名：星舒平 ），有着同类 最佳潜力，以及全球首创的普乐司兰钠注射液（商品名：瑞达普 ），填补了一处重要疾病领域的治疗空白。 实际上，赛诺菲的"心血管双子星"接连获批，也是与中国合作伙伴深度交融的结果，也是赛诺菲创新的BD（business development，业务拓展）模式的明 证。 2025年，堪称中国创新药BD交易爆发元年。医药魔方数据显示，中国创新药BD出海授权2025年交易总金额达到1356.55亿美元，再创历史新高。 在中国创新药纷纷借船出海时，赛诺菲中国则另辟蹊径。2022年底，总部授权赛诺菲中国引进管线的权力。此后，赛诺菲立足中国，主动深入中国本土创新 药生态，发掘最有潜力的药物分子，凭借自身雄厚的开发和商业化实力，让药物最早惠及中国患者。 2024年末以来，赛诺菲分别通过与箕星药业、维亚臻的BD合作，获得了阿夫凯泰片和普乐司兰钠注射液的大中华区开发及商业化权益 ...

Key Takeaways SNY beats Q4 earnings estimates. Net sales rose 7% but narrowly missed consensus.Sanofi's Dupixent sales jumped 32.2%, driven by strong prescriptions across indicationsSNY guided high single-digit sales growth in 2026, with earnings growing faster than sales.Sanofi (SNY) reported fourth-quarter 2025 adjusted earnings of 89 cents per American depositary share, which beat the Zacks Consensus Estimate of 84 cents. Earnings of €1.53 per share rose 16.8% on a reported basis and 26.7% on a constant ...

Sanofi Stock Creeps Higher On 'Essentially In Line' Guidance For 2026 | Investor's Business DailyBREAKING: [Rare Earths Stocks Skid On Policy Shift]---Sanofi (SNY) stock edged higher early Thursday after the French pharma giant reported adjusted earnings of 91 cents per share on $13.5 billion in fourth-quarter sales. Analysts polled by FactSet expected Sanofi to earn 84 cents a share and report $13.57 billion in sales. During the year-ago period, Sanofi earned 68 cents per share on $11.89 billion in sales. ...

Sanofi (NasdaqGS:SNY) Q4 2025 Earnings call January 29, 2026 08:30 AM ET Company ParticipantsBen Jackson - VP of Equity ResearchBrian Foard - EVP and Head of Specialty CareDavid Reed Risinger - Senior Managing DirectorFrançois-Xavier Roger - CFOGraham Parry - Managing Director and Head of European Pharmaceuticals Equity researchHouman Ashrafian - EVP and Head of Research and DevelopmentJames Gordon - Director and Head of European Pharma, Biotech & Life Sciences Equity ResearchJames Quigley - Executive Direc ...

Sanofi (NasdaqGS:SNY) Q4 2025 Earnings call January 29, 2026 08:30 AM ET Company ParticipantsBen Jackson - VP of Equity ResearchBrian Foard - EVP and Head of Specialty CareDavid Reed Risinger - Senior Managing DirectorFrançois-Xavier Roger - CFOGraham Parry - Managing Director and Head of European Pharmaceuticals Equity researchHouman Ashrafian - EVP and Head of Research and DevelopmentJames Gordon - Director and Head of European Pharma, Biotech & Life Sciences Equity ResearchJames Quigley - Executive Direc ...

Sanofi (NasdaqGS:SNY) Q4 2025 Earnings call January 29, 2026 08:30 AM ET Speaker7Hello everyone, this is Thomas Kudsk Larsen from the Sanofi IR team. Welcome to the Q4 and full year 2025 conference call for investors and analysts. As usual, you can find slides on sanofi.com. Please turn to slide number 3. Here we have the usual forward-looking statements. We would like to remind you that information presented in this call contains forward-looking statements which are subject to substantial risk and uncertai ...

Business Finance Pipeline Appendices Business Finance Pipeline Appendices Results Q4/FY 2025 January 29, 2026 Forward-looking statements This document contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions, and expectations with respect to fu ...

By Bhanvi Satija LONDON, Jan 29 (Reuters) - France's Sanofi, among the world's largest vaccine makers, said on Thursday that its vaccines sales would be "slightly negative" this year, partly due to U.S. policy changes under ​President Donald Trump. Sanofi is eyeing high-single-digit overall sales growth in 2026. But vaccines will remain a weak spot ‌in the United States where Health Secretary Robert F. Kennedy Jr., a longtime anti-vaccine activist, has upended official recommendations in the past year. ...